<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002729</url>
  </required_header>
  <id_info>
    <org_study_id>RC91</org_study_id>
    <nct_id>NCT01002729</nct_id>
  </id_info>
  <brief_title>Oseltamivir Pharmacokinetics in Morbid Obesity</brief_title>
  <acronym>OPTIMO</acronym>
  <official_title>Oseltamivir Pharmacokinetics in Morbid Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Center for Vaccinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IWK Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial asks the question: do people of much greater than average body weight need more of&#xD;
      a drug called oseltamivir than current recommendations suggest. Oseltamivir is a drug given&#xD;
      to people who have influenza, and currently is also being used to fight the new H1N1&#xD;
      influenza. Some people of larger than average body weight require larger amounts of drugs to&#xD;
      see the same effects as others of an average body weight. No studies have ever been conducted&#xD;
      looking at the possibility of oseltamivir being one of those drugs. Our Study's hypothesis&#xD;
      states that those of an above average body weight will have different amounts of drug in&#xD;
      their blood than those of people of normal body weight if they are given the normal amount&#xD;
      prescribed for influenza. Our study will give oseltamivir to twenty people for 7 days. Half&#xD;
      of the people will be of normal body weight and the others will be of a much higher than&#xD;
      normal body weight. Using blood samples the investigators will determine if the amounts of&#xD;
      oseltamivir are significantly lower in the blood of patients in the above normal body weight&#xD;
      group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Drug Concentration</measure>
    <time_frame>7 Days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Morbid Obesity</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with a BMI &lt; 30 given Oseltamivir</intervention_name>
    <description>Patients with a BMI &lt; 30 given Oseltamivir</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with a BMI &gt; 40 given Oseltamivir</intervention_name>
    <description>Patients with a BMI &gt; 40 given Oseltamivir</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged 18 to 55 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Subjects without medical history, physical finding or laboratory finding, which, in&#xD;
             the opinion of the investigator, could pose a safety concern or interfere with the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to oseltamivir&#xD;
&#xD;
          -  Blood donation within 3 months before oseltamivir administration&#xD;
&#xD;
          -  Medications that may interfere with the disposition of oseltamivir (e.g. probenecid)&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Estimated Creatinine clearance &lt; 60 ml/min (As calculated by the modified Cockcroft&#xD;
             Gault equation below) Creatinine Clearance= (140-Age) x 1.2 x Adjusted Body weight (x&#xD;
             0.85 if female) Serum Creatinine (umol/L)&#xD;
&#xD;
        Adjusted body weight = Ideal body weight + [0.4 (Actual Bodyweight-Ideal Body Weight)]&#xD;
&#xD;
          -  Gastrectomy&#xD;
&#xD;
          -  Enterectomy (or any other surgical procedure that would interfere with absorption)&#xD;
&#xD;
          -  Clinically significant haematological (RBC count, WBC count, WBC differential count,&#xD;
             platelets count and haemoglobin level) or biochemical (ALT, AST, creatinine and urea)&#xD;
             abnormalities as per the judgement of the investigator&#xD;
&#xD;
          -  Clinically significant cardiac conduction abnormality noted on baseline&#xD;
             electrocardiogram.&#xD;
&#xD;
          -  Influenza like illness (fever and/or cough plus one of the following sore throat,&#xD;
             fatigue, myalgia, headache) within 7 days of enrolment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to consume study meals provided due to special dietary requirements such as&#xD;
             food allergies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucas M Thorne-Humphrey, BSC Pharm</last_name>
    <role>Study Chair</role>
    <affiliation>Dalhousie Unviersity, Captial District Health Authority</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Vaccine Challenge Unit, IWK Health Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Thorne-Humphrey LM, Goralski KB, Slayter KL, Hatchette TF, Johnston BL, McNeil SA; 2009 OPTIMO Study Group. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). J Antimicrob Chemother. 2011 Sep;66(9):2083-91. doi: 10.1093/jac/dkr257. Epub 2011 Jun 23.</citation>
    <PMID>21700623</PMID>
  </results_reference>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>October 25, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>August 2, 2011</last_update_submitted>
  <last_update_submitted_qc>August 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>McNeil, Shelly</name_title>
    <organization>IWK Health Sciences Center / Capital Distict Health Authority</organization>
  </responsible_party>
  <keyword>Oseltamivir Pharmacokinetics Obesity</keyword>
  <keyword>Oseltamivir Pharmacokinetics in Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

